Preclinical studies of TRA-8, a murine DR5 agonist, in pancreatic cancer cell lines showed single-agent anti-tumor efficacy and increased efficacy in combination with doxorubicin, paclitaxel, and gemcitabine [56]. The gene discussed is TNFRSF10B; the disease is neoplasm.